A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm
Open Access
- 7 July 2020
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
Abstract
Neither the disease mechanism nor treatments for COVID-19 are currently known. Here, we present a novel molecular mechanism for COVID-19 that provides therapeutic intervention points that can be addressed with existing FDA-approved pharmaceuticals. The entry point for the virus is ACE2, which is a component of the counteracting hypotensive axis of RAS. Bradykinin is a potent part of the vasopressor system that induces hypotension and vasodilation and is degraded by ACE and enhanced by the angiotensin(1-9) produced by ACE2. Here, we perform a new analysis on gene expression data from cells in bronchoalveolar lavage fluid (BALF) from COVID-19 patients that were used to sequence the virus. Comparison with BALF from controls identifies a critical imbalance in RAS represented by decreased expression of ACE in combination with increases in ACE2, renin, angiotensin, key RAS receptors, kinogen and many kallikrein enzymes that activate it, and both bradykinin receptors. This very atypical pattern of the RAS is predicted to elevate bradykinin levels in multiple tissues and systems that will likely cause increases in vascular dilation, vascular permeability and hypotension. These bradykinin-driven outcomes explain many of the symptoms being observed in COVID-19.Funding Information
- Oak Ridge National Laboratory (Laboratory Directed Research and Development Program)
- U.S. Department of Energy (National Virtual Biotechnology Laboratory)
- National Institutes of Health (U24 HL148865)
This publication has 90 references indexed in Scilit:
- Treatment with the Hyaluronic Acid Synthesis Inhibitor 4-Methylumbelliferone Suppresses SEB-Induced Lung InflammationToxins, 2013
- The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetesMetabolism, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiencyClinical, Cosmetic and Investigational Dermatology, 2011
- Angiotensin1‐9 antagonises pro‐hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptorThe Journal of Physiology, 2011
- IcatibantBritish Journal of Clinical Pharmacology, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Release of cytokines from isolated lung strips by bradykininInflammation Research, 1995
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.JCI Insight, 1990
- Angiotensin-converting enzyme and its clinical significance--a review.Journal of Clinical Pathology, 1983